AKT1 and non-small cell lung carcinoma: Ipatasertib is a potent small-molecule kinase inhibitor with a high degree of AKT specificity that has demonstrated efficacy in various cancer cells, including ovarian cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and breast cancer.